Humacyte enters critical phase for its bioengineered tissue


A Durham company is preparing to seek federal approval for its trauma treatment in order to advance to commercialization following positive trial data.

Previous Tampa General Hospital views $25M donation to USF Athletics through community outreach lens
Next Medical office space grabs attention on the First Coast